Skip to main content

Table 2 SPARC expression in the primary tumor

From: SPARC expression in patients with high-risk localized soft tissue sarcoma treated on a randomized phase II trial of neo/adjuvant chemotherapy

  High SPARC Low SPARC No SPARC
Histology N = 22 N = 13 N = 15
 UPS 16 9 7
 LMS 2 2 2
 LPS 3 1 2
  Dedifferentiated 2 1 0
  Pleomorphic/NOS 1 0 1
  Myxoid 0 0 1
 SS 0 0 3
 MPNST 0 1 1
 FS 1 0 0
Treatment for primary prior to tumor collection
 Gemcitabine/docetaxel 14 3 3
 Doxorubicin/ifosfamide 5 9 10
 None 3 1 3
 Radiation 0 1 1
% necrosis observed in tumor after chemotherapy
 UPS 20–100 0–70 0–75
 LMS 50 80a 30
 LPS
  Dedifferentiated 15–50 0 NA
  Pleomorphic/NOS 85 NA 10
  Myxoid NA NA 90
 SS NA NA 0–80a
 MPNST NA 5 40
 FS 10 NA NA
Best Response to chemotherapy by RECIST 1.0
 Partial response 0 2 0
 Stable disease 19 8 14
 Progressive disease 3 3 1
Recurrence 9 7 5
 Local 2 4 0
 Distant 7 3 5
  1. aPt with 80 % necrosis had prior radiation